As many of you know, FARA has prepared a letter to send to the Food and Drug Administration (FDA) and Reata Pharmaceuticals to request that they Allow Individuals with Friedreich Ataxia Access to Omaveloxolone.
Read and Sign on to the letter
This letter requests Reata to submit a New Drug Application (NDA) on an urgent basis and FDA to exercise the flexibility granted by law and contained in FDA guidance in considering approval of an NDA for Omaveloxolone in FA based on the existing evidence from clinical trials.
In just four days, you have facilitated over 25,000 signatures in support of this letter! We are grateful to everyone who has signed the letter, especially members of our FA families who make up 23% of respondents. The statements and photos shared by FA families will be instrumental in drawing attention to the patient experience and voice. If you have not signed onto the letter, you can do so up until January 20th. The entire FA community (individuals with FA, family, friends, caregivers, supporters, other rare disease advocates) is invited to sign on.
Read the Full Monthly Update
Monthly Update - January 2021
- Category: News & Press Releases